Study finds bariatric surgery less costly than GLP-1 drugs over time

A new real-world analysis of more than 90,000 patients with obesity and type 2 diabetes finds metabolic and bariatric surgery costs significantly less than weekly injections of GLP-1 drugs over a two-year period, according to new research presented at the annual scientific meeting of the American Society for Metabolic and Bariatric Surgery (ASMBS2026).

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup